As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

The US FDA has accepted Novo Nordisk’s new drug application (NDA) submission for the 25 mg oral formulation of Wegovy ...

Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.

The Indianapolis-based drugmaker also reaffirmed its 2025 revenue guidance but noted that the calculation was based on existing tariff and trade policies.

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the week's most ...

Vienna, Austria – May 9th 2025 – Biomay, a leading manufacturer of recombinant proteins, today announced the commercial availability of its CRISPR/Cas9 nuclease, marking a significant addition to its ...

CVS Health Corporation ( NYSE: CVS) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET David Joyner - President, Chief Executive Officer Tom Cowhey - Executive Vice President, Chief Financial ...

The Complete Genomics platform uses a proprietary combinatorial probe–anchor ligation strategy to sequence amplified DNA templates that ... enable de novo sequencing and simplify data analysis.

Danish pharmaceutical giant Novo Nordisk and U.S. biotech Septerna agreed to collaborate on the development of pills to treat obesity, type 2 diabetes and other metabolic conditions. Under the ...